Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

ER - Lonza Group H1 2024 Performance Well On Track to Deliver Full-Year Outlook: Sales Up 1.8% CER and 29.2% CORE EBITDA Margin

Company: Lonza Group AG Date: 2024-07-25 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 News Details

Ad-hoc | 25 July 2024 06:55

#   

Lonza Group H1 2024 Performance Well On Track to Deliver Full-Year Outlook: Sales Up 1.8% CER and 29.2% CORE EBITDA Margin

Lonza Group AG / Key word(s): Half Year Results  

  

25-Jul-2024 / 06:55 CET/CEST  

Release of an ad hoc announcement pursuant to Art. 53 LR  

The issuer is solely responsible for the content of this announcement.  

  

- - -

**Ad hoc announcement pursuant to Art. 53 LR**

-   Lonza delivered sales of CHF 3.1 billion, growing 1.8% 1 CER
-   CHF 893 million CORE EBITDA resulted in a margin of 29.2%
-   Robust performance in CDMO business, with headwinds in the capsules business within the Capsules & Health Ingredients (CHI) division
-   Solid free cash flow at CHF 296 million
-   Group Outlook 2024 confirmed: flat CER sales growth and CORE EBITDA margin in high twenties
-   Mid-Term Guidance 2024 – 2028, upgraded in March, confirmed  
    

Group Financial Summary

|     |     |     |     |     |     |     |
| --- | --- | --- | --- | --- | --- | --- |
| CHF million |     | HYR 2024 |     | YoY change (in %) |     | HYR 2023 |
| Sales in AER |     | 3,057 |     | (0.7) |     | 3,078 |
| EBITDA |     | 862 |     | (4.1) |     | 899 |
| Margin in % |     | 28.2 |     |     |     | 29.2 |
| CORE EBITDA |     | 893 |     | (3.1) |     | 922 |
| Margin in % |     | 29.2 |     |     |     | 30.0 |

For more details on performance and financials, please refer to the **[Half-Year 2024 Presentation](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=ab3dd7664a0edde4d07497f343249f7a&application_id=1953479&site_id=news_data&application_name=news)** , **[Half-Year 2024 Report](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=d1539bf1d5554b8c366d51a9fedea715&application_id=1953479&site_id=news_data&application_name=news)** and [**Alternative Performance Measures (APM) 2024 Repor** t](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=580399c5a7e89476520675b423e8734b&application_id=1953479&site_id=news_data&application_name=news) .

1 Sales growth figures, expressed as a percentage (%), are at Constant Exchange Rate (CER)  

2 Actual Exchange Rate

**About Lonza**

Lonza is one of the world’s largest healthcare manufacturing organizations. Working across five continents, our global community of around 18,000 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market. United by our vision to bring any therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments.

Our business is structured to meet our customers’ complex needs across four divisions: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. Our company generated sales of CHF 3.1 billion with a CORE EBITDA of CHF 893 million in Half-Year 2024 . Find out more at **[www.lonza.com](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b128c31d5b083eb8599e8a85049f33b6&application_id=1953479&site_id=news_data&application_name=news)**

Follow @Lonza on **[LinkedIn](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=ab807bbc5d1a43334179db7493e5f5d5&application_id=1953479&site_id=news_data&application_name=news)**  

Follow @LonzaGroup on [**X**](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=f61d5571bd4ddb9125e0f8bba4f66770&application_id=1953479&site_id=news_data&application_name=news)

**Lonza Contact Details**

**Victoria Morgan**

Head of External Communications  

Lonza Group Ltd  

Tel +41 61 316 2283  

[victoria.morgan@lonza.com](mailto:victoria.morgan@lonza.com)

**Daniel Buchta**  

Investor Relations  

Lonza Group Ltd  

Tel +41 61 316 2985  

[daniel.buchta@lonza.com](mailto:daniel.buchta@lonza.com)

  

- - -

End of Inside Information

- - -

|     |     |
| --- | --- |
| Language: | English |
| Company: | Lonza Group AG |
|     | Münchensteinerstrasse 38 |
|     | 4052 Basel |
|     | Switzerland |
| Phone: | +4161 316 81 11 |
| Internet: | www.lonza.com |
| ISIN: | CH0013841017 |
| Valor: | 1384101 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1953479 |

  

|     |     |
| --- | --- |
|     |     |
| End of Announcement | EQS News Service |

![show this](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1953479&application_name=news&site_id=news_data)